The news of Janux Therapeutics considering a sale following interest from larger pharmaceutical firms has positively impacted its stock price. The engagement of a financial adviser to explore options further validates the company's value proposition in the market, especially given its focus on innovative cancer treatments. This development, coupled with the company's recent financial success and promising treatment data, suggests a strong short-term bullish outlook for JANX shares.